Hyperkalemic Effects of Triamterene
Authors: A B Cohen
Journal: Annals of Internal Medicine (1966)

Article1 September 1966Hyperkalemic Effects of TriamtereneALLEN B. COHEN, M.D.ALLEN B. COHEN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-65-3-521 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTriamterene (2,4,7-triamino-6-phenylpteridine),* a potassium-retaining diuretic, has been used since 1961 (1). Its principal effect is on the distal tubule where it inhibits sodium reabsorption and potassium secretion (2). It behaves like an aldosterone antagonist but functions in adrenalectomized animals (3) and in patients when aldosterone has been chemically blocked (3, 4).Triamterene has been used in the treatment of various edematous states, including congestive heart failure, hepatic cirrhosis with ascites, and the nephrotic syndrome. Most studies have been short term and have involved groups of patients who were heterogeneous with respect to age and disease (5-9). Baba, Tudhope, and Wilson...References1. LARAGHREILLYSITESANGERS JHEBTM: Pteridine compounds as an inhibitor of aldosterone action in man. Fed. Proc. 20: 410, 1961. Google Scholar2. NIELSENLASSEN OEJB: Triamterene activity investigated by the stop-flow technique and in vitro studies on carbonic anhydrase. Acta Pharmacol (Kobenhavn) 20: 351, 1963. CrossrefMedlineGoogle Scholar3. LIDDLE GW: Symposium: Adrenal Steroids, specific and non-specific inhibition of mineralocorticoid activity. Metabolism 10: 1021, 1961. Google Scholar4. BABATUDHOPEWILSON WIGRGM: Triamterene, a new diuretic drug. I. Studies in normal men and adrenalectomized rats. Brit. Med. J. 1: 756, 1962. CrossrefGoogle Scholar5. BABATUDHOPEWILSON WIGRGM: Triamterene, a new diuretic drug, II. Clinical trial in oedematous patients. Ibid., p. 760. Google Scholar6. ANICHINIGARGANOBARTORELLI MNC: Triamterene, a supposed aldosterone inhibitor. Diuretic activity in edematous subjects. (Fr.) Presse Med. 71: 123, 1963. MedlineGoogle Scholar7. CATTELL WR: Triamterene. Practitioner 190: 794, 1963. MedlineGoogle Scholar8. DONNELLYTURNERSOWRY RJPGS: Clinical trial of new oral diuretic-SKF 8542. Lancet 1: 245, 1962. CrossrefMedlineGoogle Scholar9. QUANKAHANA KCL: Clinical experience with the diuretic effects of triameterene alone and combined with hydrochlorothiazide. Curr. Ther. Res. 6: 27, 1964. MedlineGoogle Scholar10. HEATHFREIS WCE.: Triamterene with hydrochlorothiazide in the treatment of hypertension. JAMA 186: 119, 1963. CrossrefMedlineGoogle Scholar11. NIELSEN OE: Triamterene. Clinical investigations on the diuretic and potassium retaining effect during combined treatment with a chlorothiazide derivative (trichlormethiazide) and on the effect of the preparation on renal filtration. (Dan.). Ugeskr. Laeg. 126: 290, 1962. Google Scholar12. SHALDONRYDER SJA: Use of a pteridine diuretic (triamterene) in treatment of hepatic ascites. Brit. Med. J. 2: 764, 1964. CrossrefGoogle Scholar13. CROSLEYRONQUILLOSTRICKLANDALEXANDER APLMWHF: Triamterene, a new natriuretic agent. Preliminary observations in man. Ann. Intern. Med. 56: 241, 1962. LinkGoogle Scholar14. JOOSSENSVERWILGENVERBERCKMOES JVRR: Triamterene combined with other diuretics in congestive heart failure. Acta Cardiol. (Brux.) 19: 32, 1964. MedlineGoogle Scholar15. LENZIRAVENNI FC: Some particular aspects of the action of triamterene on potassium metabolism. (It.) Arch. Pat. Clin. Med. 40 (suppl.): 3046, 1963. Google Scholar16. SHOCK NW: The role of the kidney in electrolyte and water regulation in the aged, in Ciba Foundation Colloquia on Aging, vol. 4. Little, Brown and Co., Boston, 1959, p. 229. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: St. Louis, MissouriFrom the Washington University Department of Medicine, Barnes Hospital, and Cochran Veterans Administration Hospital, St. Louis, Mo.Requests for reprints should be addressed to Allen B. Cohen, M.D., 6721 Townbrook Dr., Apt. C, Baltimore, Md. 21207.*Dyrenium®. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMolecular modeling studies of fused pyrimidine derivatives at various receptorsSodium Imbalance in Mice Results Primarily in Compensatory Gene Regulatory Responses in Kidney and Colon, but Not in Taste TissueDrug-Induced HyperkalemiaClinical Laboratories for the Practicing Pharmacist: General Serum ChemistryFixed-Dose Combination Diuretics in Congestive Heart Failure: An EvaluationChange in Antikaliuretic Response to Potassium-Sparing Diuretics in Patients with Cirrhotic AscitesREFERENCESDiuretic therapy-current statusPossible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)ChylothoraxHyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosisTreatment of the Patient With Refractory Heart FailureHYPERKALEMIC CHANGES DURING SPIRONOLACTONE THERAPY FOR CIRRHOSIS AND ASCITES, WITH SPECIAL REFERENCE TO HYPERKALEMIC INTERMITTENT PARALYSIS 1 September 1966Volume 65, Issue 3Page: 521-527KeywordsAldosteroneAttentionCirrhosisDiureticsElectrocardiographyHeart failureHospital medicineIntoxicationPotassiumSodium ePublished: 1 December 2008 Issue Published: 1 September 1966 PDF downloadLoading ...